Heart fat targeted: new drug combo may lower attack risk
NCT ID NCT07297589
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two diabetes medications (SGLT2 inhibitors and GLP-1 agonists) to see if they can reduce epicardial fat—the fat around the heart—in people who recently had a heart attack. About 136 participants with type 2 diabetes and obesity will have their heart fat measured by CT scan at the start and after 12 months of treatment. The goal is to find a way to lower future heart risks by targeting this specific fat.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPICARDIAL FAT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Unidad Medica de Alta Especialidad No. 1, Bajío
RECRUITINGLeón, Guanajuato, 37260,, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive chest pain registry reveals gaps between guidelines and real-world care in china
- Simple arm cuff before angioplasty may boost heart attack recovery
- Suction device may improve outcomes in heart attack patients with large clots
- New One-Hour blood test could speed up heart attack diagnosis
- AI blood test could spot heart attacks faster
- Heart attack patients may benefit from Clot-Busting drug before delayed procedure